Neurological & CognitiveResearch OnlyS

P21

Nootropic Peptide Candidate

Experimental neurocognitive peptide candidate with limited human evidence.

XRedditFacebook
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
Studies cited
2
Research grade
S
Community score
168

Trend index

Trackers
3,751

Overview

About P21

Experimental neurocognitive peptide candidate with limited human evidence.

Category
Neurological & Cognitive
Regulatory status
Research Only
Also known as
Nootropic Peptide Candidate
Self-reports
6

Community

What 6 users report

6 community reports

Positive 100% · Neutral 0% · Negative 0%

Most reported benefits

Cognition
6
Mood
6
Sleep
3

Dose distribution

Median: 200–400 mcg · Most common: 200–400 mcg

0–25
0
25–50
0
50–100
0
100–200
2
200–400
4
400–600
0
600–1000
0
1000–2000
0
2000+
0

Commonly stacked with

Research

Cited research (1)

Help

Frequently asked

What do PeptIQ users report about P21?

This page summarizes 6 anonymized self-reports from PeptIQ users who track P21, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.

What research is cited for P21?

1 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.

Is P21 safe to use?

This wiki does not assess safety or recommend use. P21 is listed as Research Only. Consult a licensed clinician for personal medical decisions.

What are the purported benefits and uses of P21?

Research, primarily in animal models, suggests P21 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.

Source

What is the legal status of P21?

P21 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified P21 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.

Source

What are the known or theoretical side effects and risks of P21?

The safety and effectiveness of P21 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.

Source

What is the current state of research on P21?

While there are over 200 published studies on P21, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.

Source